Transcription
Two alternative splicing products; 5624bp (coding, 1578bp ORF) and 313bp (non-coding). A 1.5kb upstream sequence presents CG-rich and pyrimi-dinerich regions and contains consensus sequences for the recognition sites of Sp-1, AP-2, INF-gamma responsive element, GATA, NF-kB, glucocorticoid responsive element and a CACCC box. It has been demonstrated that PTGIS transcription is regulated via Sp1 binding, which may affected by polymorphisms in the promoter region. The CG-rich region presents significant promoter activity.
Localisation
At cellular level can be found in the endoplasmatic reticulum membrane and in microsomes as a peripheral membrane protein.
Function
Catalyses the isomerization of prostaglandin H2 to prostacyclin (prostaglandin I2), a potent vasodilator and inhibitor of platelet aggregation.
Homology
Pan troglodytes -Prostaglandin I2 (prostacyclin) Synthase. Canis lupus familiaris -Prostaglandin I2 (prostacyclin) Synthase. Bos taurus -Prostaglandin I2 (prostacyclin) Synthase. Mus musculus -Prostaglandin I2 (prostacyclin) Synthase. Rattus norvegicus -Prostaglandin I2 (prostacyclin) Synthase. Danio rerio -Prostaglandin I2 (prostacyclin) Synthase like.
Mutations

Note
One splicing mutation has been associated with essential hypertension.
Implicated in
Colorectal cancer
Note PTGIS promoter is silenced by through promoter hypermethylation in a large subset of colorectal carcinomas (also observed in colorectal adenomas and in several colorectal cancer cell lines). The PTGIS silencing is an early event on tumor progression and age and sex-independent. A PTGIS promoter VNTR polymorphism has been associated with the risk of colorectal polyps, being the risk increased when both alleles present less than 6 repeats.
Non-small cell lung cancer
Disease PTGIS promoter is hypermethylated in lung cancer cell lines. The VNTR polymophism has also been associated with gene silencing in lung cancer cells.
Breast cancer
Disease
The combination of the SNPs PTGIS(11)rs477627, PTGIS(21)rs476496 and PTGIS(20)rs1066894, located in the 5' region and first intron, confers reduced susceptibility to breast cancer.
Essential hypertension
Disease A splicing mutation (T->C at the +2 position of the donor site of the intron 9) alters the reading frame and results in the production of a truncated protein with the heme-binding region deleted. The subjects found with this mutation presented lower levels of prostacyclin and hypertension. The polymorphism C1117A has been significantly associated with hypertension, being the allele C associated with higher risk the condition, although it does not change the aminoacid sequence. A polymorphism in the 5' region with a variable number of repeats of a 9-bp sequence (CCGCCAGCC) is associated with hypertension. The alleles less repeats possess less Sp1 sites and present lower promoter activity, being related with
